Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CGON vs RGNX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CGON Captures Overall Composite Edge (45.0 HOLD vs 45.3 HOLD), While RGNX Leads 4–2 on Growth & Valuation Pillars
CGON Overall Winner
6-Pillar Tally: CGON 2 – 4 RGNX
Matrix Metrics: CGON 5 – 3 RGNX
As of Nov 16, 2026, CG Oncology, Inc. (CGON) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (45.0/100 HOLD vs. 45.3/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale, Options & Positioning), while RGNX wins 4–2 across the 6-pillar growth and valuation breakdown. CGON trades at $84.94 (N/M Forward P/E, -4293.5% operating margin) versus RGNX at $7.45 (N/M Forward P/E, -120.4% operating margin).
- Growth vs. Quality Trade-Off: CGON earns the overall head-to-head edge with a stronger Unified Composite Score (45.0/100 HOLD vs. RGNX 45.3/100 HOLD) and 0.77β · 86% Vol risk profile, whereas RGNX leads top-line expansion (-69.2% YoY revenue growth, 0.26x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: CGON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 71.7); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CGON vs RGNX
CGON
Head-to-Head Winner
CG Oncology, Inc. Common stock
$84.94
+14.16% 1D
Market Cap
$6.3B
TTM Revenue
$6.2M
Forward P/E
N/M
Beta / 30D Vol
0.77β · 86% Vol
Unified Composite Score
45.0
HOLD
Tech 15.0
Fund 44.0
Flow 69.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
RGNX
REGENXBIO Inc.
$7.45
-2.49% 1D
Market Cap
$500.9M
TTM Revenue
$154M
Forward P/E
N/M
Beta / 30D Vol
1.82β · 76% Vol
Unified Composite Score
45.3
HOLD
Tech 36.0
Fund 44.0
Flow 69.0
Mom 50.0
Weinstein Technical Phase
Distribution · Trim / tighten stop
6-Pillar Scorecard Institutional Category Breakdown (CGON 2 – 4 RGNX)
1. Valuation Multiples
RGNX
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
0.26x
EV / Revenue
N/M
3.1x
2. Growth & Scale
CGON
Revenue Growth (YoY)
-3.7%
-69.2%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$6.2M
$154M
Market Cap
$6.3B
$500.9M
3. Profitability & Quality
RGNX
Gross Margin
N/A
-64.5%
Operating Margin
-4293.5%
-120.4%
Net Profit Margin
0.0%
-113.9%
Return on Equity (ROE)
-28.3%
-113.2%
4. Balance Sheet & Cash Flow
RGNX
Cash Generation (TTM)
-$189M
-$155M
Cash Flow Margin
N/A
-100.6%
Net Cash / Leverage
$19M Net Cash
$29M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CGON
Options Structure Phase
CONSOLIDATION
BREAKDOWN
Current IV / %ile
238.6% (85th %ile)
349.6% (52nd %ile)
Put/Call OI Skew
0.35x (Call-Skewed)
N/A
OBV Trend / Tech Phase
ACCUMULATION · Neutral
ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat
RGNX
OpEx & R&D Intensity
N/A
55.9% of Rev ($86M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CGON (5) vs RGNX (3)| Institutional Metric | CGON | RGNX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $6.3B | $500.9M | CGON | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -3.7% | -69.2% | CGON | |
| Operating Margin (TTM) | -4293.5% | -120.4% | RGNX | |
| Net Profit Margin | 0.0% | -113.9% | CGON | |
| Return on Equity (ROE) | -28.3% | -113.2% | CGON | |
| 52-Week Range Position | 84% ($37–$94) | 19% ($5–$16) | CGON | |
| Beta / 30D Volatility | 0.77β · 86% Vol | 1.82β · 76% Vol | RGNX | |
| Unified Institutional Score | 45.0 / 100 (HOLD) | 45.3 / 100 (HOLD) | RGNX | |
| Trailing 12M Revenue (USD) | $6.2M | $154M | Scale | |
| Gross Profit Margin (TTM) | N/A | -64.5% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | 0.26x PEG · 3.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$189M ($19M Net Cash) | -$155M ($29M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CGON +34.33 pp
3M Horizon
CGON +44.03 pp
6M Horizon
CGON +3.11 pp
1Y Horizon
CGON +160.93 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CGON Revenue | RGNX Revenue | CGON Op. Margin | RGNX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $220M | N/A | 40.3% | RGNX |
| FY2019 | N/A | $40M | N/A | -422.9% | RGNX |
| FY2020 | N/A | $150M | N/A | -77.1% | RGNX |
| FY2021 | N/A | $470M | N/A | 34.0% | RGNX |
| FY2022 | N/A | $110M | N/A | -233.2% | RGNX |
| FY2023 | $0M | $90M | -27180.9% | -297.1% | RGNX |
| FY2024 | $0M | $80M | -10067.3% | -280.0% | RGNX |
| FY2025 | $0M | $170M | -4722.1% | -94.6% | RGNX |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CGON
CONSOLIDATION
Current IV
238.6%
IV Percentile
85th %ile
Put/Call OI Skew
0.35x (Call-Skewed)
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact CGON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
RGNX
BREAKDOWN
Current IV
349.6%
IV Percentile
52nd %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CGON Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
RGNX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
55.9% of Rev ($86M)
90D Engineering Disclosures
0 Published
Investor FAQ CGON vs RGNX Key Questions & Quantitative Answers
As of Nov 16, 2026, CG Oncology, Inc. (CGON) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (45.0/100 HOLD vs. 45.3/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale, Options & Positioning), while RGNX wins 4–2 across the 6-pillar growth and valuation breakdown. CGON trades at $84.94 (N/M Forward P/E, -4293.5% operating margin) versus RGNX at $7.45 (N/M Forward P/E, -120.4% operating margin). Growth vs. Quality Trade-Off: CGON earns the overall head-to-head edge with a stronger Unified Composite Score (45.0/100 HOLD vs. RGNX 45.3/100 HOLD) and 0.77β · 86% Vol risk profile, whereas RGNX leads top-line expansion (-69.2% YoY revenue growth, 0.26x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CGON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 71.7); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CGON leads the Growth & Scale pillar: CGON posts -3.7% YoY revenue growth and +0.0% YoY earnings growth on $6.2M TTM revenue (N/A gross margin, -4293.5% operating margin), compared with RGNX at -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CGON cumulative revenue shifted N/A while RGNX shifted -22.7%. In operating R&D and SG&A reinvestment, CGON deploys N/A (0 90-day corporate R&D disclosures) versus 55.9% of Rev ($86M) (0 disclosures) for RGNX.
RGNX screens cheaper on headline valuation multiples. CGON trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGON (-28.3% ROE) versus RGNX (-113.2% ROE) capital efficiency.
In options market volatility and institutional positioning, CGON carries 238.6% implied volatility (85th %ile, Extreme (>80th %ile)), a 0.35x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.77β · 86% Vol realized risk). By comparison, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
RGNX vs CGON · Reverse Pair
CGON vs AVBP
· Sector Peer
CGON vs SYRE
· Sector Peer
CGON vs MLYS
· Sector Peer
RGNX vs QURE
· Sector Peer
RGNX vs MGTX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem